David Turkaly, an analyst from JMP Securities, reiterated the Buy rating on TELA Bio (TELA – Research Report). The associated price ...

TELA Bio, Inc. (NASDAQ: TELA) has announced impressive financial results for the third quarter of 2024, achieving a record ...

The company said, “Reiterated full year 2024 revenue guidance of $74.5 million to $76.5 million, representing 27% to 31% year-over-year ...

The skies will be mostly cloudy. The high will reach 87° on this humid day. Good air quality (0-50) Primary pollutant O₃ 58 μg/m³ Pressure is the weight of the air in the atmosphere. It is normalized ...

For Tela, there aren’t any characteristics of Trump’s masculinity that resonate with him. Trump’s comments about Haitian ...

Revenue: US$19.0m (up 26% from 3Q 2023). Net loss: US$10.4m (loss narrowed by 5.3% from 3Q 2023). US$0.42 loss per share (improved from US$0.45 loss in 3Q 2023). Revenue was in line with analyst ...

TELA Bio Inc (NASDAQ:TELA) reported a strong third quarter with a 26% year-over-year revenue increase, reaching $19 million. The company experienced significant growth in its European business ...

TELA has been the subject of a number of research reports. Lake Street Capital reduced their target price on shares of TELA Bio from $14.00 to $8.00 and set a “buy” rating for the company in a ...

Everard Best met Téla D’Amore on the streets of New York City’s Lower East Side . Years later, the duo would helm a defining ...

MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction ...

Full Year Revenue Guidance: $74.5 million to $76.5 million for 2024, reflecting growth of 28% to 31% over 2023. TELA Bio Inc ...